Maze Therapeutics (NASDAQ:MAZE) Insider Sells 1,981 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Phillips Courtney sold 1,981 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $26.47, for a total value of $52,437.07. Following the completion of the transaction, the insider directly owned 9,019 shares in the company, valued at $238,732.93. This trade represents a 18.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

• Biotech Breakouts: 3 Stocks With Massive Upside Potential

Phillips Courtney also recently made the following trade(s):

• On Thursday, September 3rd, Phillips Courtney sold 2,012 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12.

Maze Therapeutics Stock Up 1.3%

Shares of Maze Therapeutics stock opened at $26.21 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The business has a 50-day moving average of $28.69 and a 200-day moving average of $31.17. The company has a market capitalization of $1.46 billion, a PE ratio of -10.40 and a beta of 2.17. Maze Therapeutics, Inc. has a 1-year low of $14.27 and a 1-year high of $53.65.

---

---

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). As a group, equities analysts forecast that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. ARCH Venture Management LLC bought a new position in shares of Maze Therapeutics in the second quarter worth about $122,983,582. Alphabet Inc. acquired a new position in shares of Maze Therapeutics in the second quarter valued at $41,435,000. TRV GP IV LLC bought a new position in shares of Maze Therapeutics during the 2nd quarter worth about $133,502,907. Spruce Street Capital LP bought a new position in Maze Therapeutics during the first quarter worth about $5,970,000. Finally, Boothbay Fund Management LLC lifted its position in shares of Maze Therapeutics by 16.3% during the 4th quarter. Boothbay Fund Management LLC now owns 409,372 shares of the company's stock worth $16,960,000 after buying an additional 57,497 shares during the period.

Key Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Wall Street Zen cut Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Finally, BTIG Research reissued a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $66.00.

Check Out Our Latest Research Report on Maze Therapeutics

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

Featured Articles

• Five stocks we like better than Maze Therapeutics
• MarketBeat Week in Review – 08/31 - 09/04
• Revolution Medicines Got Its Breakthrough—What Moves It Next?
• Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
• FB Financial's Southern Expansion and Buybacks Drive Analyst Optimism

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].